pharmaphorum Deep Dive digital magazine pharmaceutical industry

pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven views, analysis, high-level interviews and unique research for pharmaceutical companies, biotech firms and the wider healthcare sector.

In 2019 Deep Dive will have special focuses on disruptive technologies in pharma, R&D innovation, market access & commercialisation, oncology, sales & marketing innovation, digital health and patient engagement. (Sign-up here to receive future issues of Deep Dive direct to your inbox.)

To discuss paid-for article options, including feature series, issue sponsorship and bespoke versions of the digital magazine, please email advertising@pharmaphorum.com.

Oncology and ASCO 2019Deep Dive: Oncology and ASCO 2019

In this issue of Deep Dive we look at the most important trends in modern oncology, starting with an analysis of this year’s ASCO conference featuring thought leaders from Kantar. Meanwhile, experts from ICON, Cytel, Research Partnership, and Pharmerit give their views on how to tackle the biggest challenges in this dynamic disease area. Elsewhere, we have exclusive interviews with Astellas US president Percival Barretto-Ko, Impetus Digital’s Natalie Yeadon, and Tag’s Robb DeFilippis.

• Deep Dive: Oncology and ASCO 2019 contents

 

Access and CommercialisationDeep Dive: Access and Commercialisation

In this issue of Deep Dive we explore the ever present issues of market access and commercialisation, analysing recent changes to market access in China, England and the US and asking how pharma can work with healthcare systems to ensure patients get the medicines they need. Plus there’s a focus on new ways the industry can harness digital innovation. Read on for expert views from Research Partnership, ICON, Impetus Digital and IDEA Pharma, as well as interviews with Sandoz’s Andre Heeg, LEO Innovation Lab’s John Zibert and Janssen’s Kris Sterkens.

• Deep Dive: Access and Commercialisation contents

 

R-and-D-Innovation-2019Deep Dive: R&D Innovation

In this issue of Deep Dive Magazine we look at innovation in R&D, asking how pharma can change up the development model with new strategies and technologies to cut waste and ensure the best medicines get to the patients that can benefit from them. Plus, we have a special focus on rare disease patients and how to best meet their needs. There’s expert input from IDEA Pharma, Havas Lynx Faze, Johnson & Johnson, AstraZeneca, Alexion and Spire Health, as well as rare disease advocates Seth Rotberg and Ana Velosa.

• Deep Dive: R&D Innovation contents

 

Deep Dive Disruptive Technologies in pharmaDeep Dive: Disruptive Technologies

In the first issue of Deep Dive for 2019, we look at disruptive technologies in pharma, how they’re changing medicine, research and development, and healthcare, and how the pharmaceutical industry is responding to these momentous shifts.

There’s expert input from Pfizer, Johnson & Johnson, AstraZeneca, Bayer, Sandoz and a host of other digital health movers and shakers, plus thought-leadership from Evidera, Syneos Health and the Digital Therapeutics Alliance (DTA).

• Deep Dive: Disruptive Technologies contents

Deep Dive Digital Health InnovationDeep Dive: Digital Health Innovation

This bespoke edition of pharmaphorum’s regular Deep Dive digital magazine was produced in partnership with Healthware International and Frontiers Health.

It investigates the digital health ecosystem with input from investors, start-up founders, pharma executives and many more to look at the convergence of digital and traditional medicine, the pace of healthcare technology adoption and the transformation of patient outcomes.

• Read Deep Dive: Digital Health Innovation in full

Deep Dive Oncology special - reflections on ASCODeep Dive: Oncology special – reflections on ASCO

Highlights from our Oncology special include an interview with Merck & Co’s Roy Baynes on Keytruda, plus further insights from ASCO 2018 into CAR-T cell therapies, reviews of the latest prostate and breast cancer research and how digital technology could help diagnosis.

We also hear from Witty Health on blockchain technology and from Oncolytics Biotech’s Matt Coffey about the oncolytic virus renaissance. Plus, health economist Leela Barham reviews the latest ways to assess the worth of new cancer drugs.

• Read Deep Dive: Oncology special – reflections on ASCO in full

Deep Dive Future PharmaDeep Dive: Future Pharma

This Future Pharma issue brings forth evidence of what the likely future is for our industry, what this means for healthcare and how pharma can best navigate the sea of change ahead to ensure a successful and sustainable future.

Chris Molloy of the Medicines Discovery Catapult explains why the future of medical innovation lies with the industry’s SMEs, Karen Taylor of Deloitte offers six predictions for the course of our industry and there’s a look at how nanotechnology is now advancing medicine.

• Read Deep Dive: Future Pharma in full

Deep Dive Patient CentricityDeep Dive: Patient Centricity

The phrase ‘patient centricity’ has been a buzzword for some time in the industry, but how many pharmaceutical companies are merely paying it lip service? Are there firms that truly understand and have taken steps to reorganise their approach, internally and externally?

Though patient organisations and charities may feel pharma has a long way to go, this edition of Deep Dive features many examples where companies have listened and partnerships have resulted in improvements to patients’ lives – and the bottom line.

• Read Deep Dive: Patient Centricity in full

Deep Dive DigitalDeep Dive: Digital

There are an increasing number of digital health companies working to capture and analyse data that can be used to improve areas such as patient outcomes, clinical trial recruitment and real-world outcomes.

As pharma companies work to blend digital into their processes, this Deep Dive edition hears from the experts about how to navigate the challenges that remain and make the most of the sector’s data-driven future.

• Read Deep Dive: Digital in full

Deep Dive: Market Access

Ultimately, market access is about ensuring effective treatments reach the people who need them. There are many components that must fit together along that journey, as explored by our expert contributors in this edition.

Just some of the themes include: the real impact of a Health Technology Assessment (HTA) decision, the promise of the ‘MINT’ countries (Mexico, Indonesia, Nigeria and Turkey) and a step-by-step guide to the generation and use of real-world data.

• Read Deep Dive: Market Access in full

Deep Dive: Future Pharma

The 2017 Future Pharma issue of Deep Dive comes as healthcare faces transformation as tech companies move into the sector and, in turn, pharmaceutical firms partner with them to develop novel solutions for patient monitoring, adherence, improving clinical trials, big data analysis, and recording the real-world effects of therapies, to name just a few.

Add proactive patients and tailored drug advances and the future looks both exciting and uncertain.

• Read Deep Dive: Future Pharma in full

Deep Dive OncologyDeep Dive: Oncology

Advances in treatments are revolutionising cancer management, but with more people living longer with cancer, is the wider support infrastructure for patients and carers adequate?

This edition also examines the latest immuno-oncology techniques, the question of affordability, and the cutting-edge research being funded by Cancer Research UK’s Grand Challenge programme.

• Read Deep Dive: Oncology in full

Deep Dive: Patient Centricity

What does ‘patient centricity’ really mean? And what does it look like in practice? Can embedding a person-centred approach in an organisation be a win for the company as well as the patient?

The European Patients Forum, European Society for Person Centred Healthcare, Findacure and the EMA’s Patients’ and Consumers’ Working Party, outline examples of best practice and areas for further development in this issue of Deep Dive.

• Read Deep Dive: Patient Centricity in full

Deep Dive DigitalDeep Dive: Digital

This 2016 issue of Deep Dive examines the use of digital health technologies, ranging from data management and real-world evidence, to industry initiatives and best practice in social media, plus we look at how to get the most from gamification and scientific animation.

Read the views of some of the top minds in the field, from companies and organisations, including IBM Watson Health, Twitter, the ABPI and EACA, and learn what’s next in the digital revolution.

• Read Deep Dive: Digital in full

Deep Dive Market AccessDeep Dive: Market Access

This 2016 debut edition of pharmaphorum’s Deep Dive digital magazine brings you intelligent insights on market access in a series of in-depth articles and opinion pieces from industry thought leaders, patient group experts and our pharma journalists.

Read a keynote from EFPIA’s director general on how the industry is willing to partner with payers to overcome the challenge of rising demand from ageing populations and chronic diseases.

• Read Deep Dive: Market Access in full

CONTINUE TO SITE >
X
Close in 10 seconds